1
|
Fusée L, Salomao N, Ponnuswamy A, Wang L, López I, Chen S, Gu X, Polyzoidis S, Vadivel Gnanasundram S, Fahraeus R. The p53 endoplasmic reticulum stress-response pathway evolved in humans but not in mice via PERK-regulated p53 mRNA structures. Cell Death Differ 2023; 30:1072-1081. [PMID: 36813920 PMCID: PMC10070458 DOI: 10.1038/s41418-023-01127-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Revised: 01/27/2023] [Accepted: 02/01/2023] [Indexed: 02/24/2023] Open
Abstract
Cellular stress conditions activate p53-dependent pathways to counteract the inflicted damage. To achieve the required functional diversity, p53 is subjected to numerous post-translational modifications and the expression of isoforms. Little is yet known how p53 has evolved to respond to different stress pathways. The p53 isoform p53/47 (p47 or ΔNp53) is linked to aging and neural degeneration and is expressed in human cells via an alternative cap-independent translation initiation from the 2nd in-frame AUG at codon 40 (+118) during endoplasmic reticulum (ER) stress. Despite an AUG codon in the same location, the mouse p53 mRNA does not express the corresponding isoform in either human or mouse-derived cells. High-throughput in-cell RNA structure probing shows that p47 expression is attributed to PERK kinase-dependent structural alterations in the human p53 mRNA, independently of eIF2α. These structural changes do not take place in murine p53 mRNA. Surprisingly, PERK response elements required for the p47 expression are located downstream of the 2nd AUG. The data show that the human p53 mRNA has evolved to respond to PERK-mediated regulation of mRNA structures in order to control p47 expression. The findings highlight how p53 mRNA co-evolved with the function of the encoded protein to specify p53-activities under different cellular conditions.
Collapse
Affiliation(s)
- Leila Fusée
- Inserm U1131, 27 Rue Juliette Dodu, 75010, Paris, France
| | - Norman Salomao
- Inserm U1131, 27 Rue Juliette Dodu, 75010, Paris, France
| | | | - Lixiao Wang
- Department of Medical Biosciences, Umea University, 90185, Umea, Sweden
| | - Ignacio López
- Biochemistry-Molecular Biology, Faculty of Science, Universidad de la República, Iguá 4225, 11400, Montevideo, Uruguay
| | - Sa Chen
- Department of Medical Biosciences, Umea University, 90185, Umea, Sweden
| | - Xiaolian Gu
- Department of Medical Biosciences, Umea University, 90185, Umea, Sweden
| | - Stavros Polyzoidis
- Department of Neurosurgery, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | | | - Robin Fahraeus
- Inserm U1131, 27 Rue Juliette Dodu, 75010, Paris, France. .,Department of Medical Biosciences, Umea University, 90185, Umea, Sweden. .,RECAMO, Masaryk Memorial Cancer Institute, Zluty kopec 7, 65653, Brno, Czech Republic.
| |
Collapse
|
2
|
Salomao N, Maslah N, Giulianelli A, Drevon L, Aguinaga L, Gu X, Cassinat B, Giraudier S, Fenaux P, Fahraeus R. Reduced murine double minute 2 and
4
protein, but not
messenger RNA
, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia. Br J Haematol 2022; 201:234-248. [PMID: 36546586 DOI: 10.1111/bjh.18608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Revised: 12/04/2022] [Accepted: 12/05/2022] [Indexed: 12/24/2022]
Abstract
The human homologues of murine double minute 2 (MDM2) and 4 (MDM4) negatively regulate p53 tumour suppressor activity and are reported to be frequently overexpressed in human malignancies, prompting clinical trials with drugs that prevent interactions between MDM2/MDM4 and p53. Bone marrow samples from 111 patients with acute myeloblastic leukaemia, myelodysplastic syndrome or chronic myelomonocytic leukaemia were examined for protein (fluorescence-activated cell sorting) and messenger RNA (mRNA) expression (quantitative polymerase chain reaction) of MDM2, MDM4 and tumour protein p53 (TP53). Low protein expression of MDM2 and MDM4 was observed in immature cells from patients with excess of marrow blasts (>5%) compared with CD34+ /CD45low cells from healthy donors and patients without excess of marrow blasts (<5%). The mRNA levels were indistinguishable in all samples examined regardless of disease status or blast levels. Low MDM2 and MDM4 protein expression were correlated with poor survival. These data show a poor correlation between mRNA and protein expression levels, suggesting that quantitative flow cytometry analysis of protein expression levels should be used to predict and validate the efficacy of MDM2 and MDM4 inhibitors. These findings show that advanced disease is associated with reduced MDM2 and MDM4 protein expression and indicate that the utility of MDM2 and MDM4 inhibitors may have to be reconsidered in the treatment of advanced myeloid malignancies.
Collapse
Affiliation(s)
- Norman Salomao
- Inserm UMRS1131, Institut de Recherche Saint‐Louis, Institut de Génétique Moléculaire, Université de Paris‐Cité, Hôpital St. Louis Paris France
| | - Nabih Maslah
- Inserm UMRS1131, Institut de Recherche Saint‐Louis, Institut de Génétique Moléculaire, Université de Paris‐Cité, Hôpital St. Louis Paris France
| | - Anouk Giulianelli
- Service d'Hématologie Senior—Hôpital Saint‐Louis—Assistance Publique Hôpitaux de Paris, and Paris Cité university Paris France
| | - Louis Drevon
- Inserm UMRS1131, Institut de Recherche Saint‐Louis, Institut de Génétique Moléculaire, Université de Paris‐Cité, Hôpital St. Louis Paris France
- Service d'Hématologie Senior—Hôpital Saint‐Louis—Assistance Publique Hôpitaux de Paris, and Paris Cité university Paris France
| | - Lorea Aguinaga
- Inserm UMRS1131, Institut de Recherche Saint‐Louis, Institut de Génétique Moléculaire, Université de Paris‐Cité, Hôpital St. Louis Paris France
- Service d'Hématologie Senior—Hôpital Saint‐Louis—Assistance Publique Hôpitaux de Paris, and Paris Cité university Paris France
| | - Xiaolian Gu
- Department of Medical Biosciences Building 6M, Umeå University Umeå Sweden
| | - Bruno Cassinat
- Inserm UMRS1131, Institut de Recherche Saint‐Louis, Institut de Génétique Moléculaire, Université de Paris‐Cité, Hôpital St. Louis Paris France
- Service d'Hématologie Senior—Hôpital Saint‐Louis—Assistance Publique Hôpitaux de Paris, and Paris Cité university Paris France
| | - Stephane Giraudier
- Inserm UMRS1131, Institut de Recherche Saint‐Louis, Institut de Génétique Moléculaire, Université de Paris‐Cité, Hôpital St. Louis Paris France
- Service d'Hématologie Senior—Hôpital Saint‐Louis—Assistance Publique Hôpitaux de Paris, and Paris Cité university Paris France
| | - Pierre Fenaux
- Service d'Hématologie Senior—Hôpital Saint‐Louis—Assistance Publique Hôpitaux de Paris, and Paris Cité university Paris France
| | - Robin Fahraeus
- Inserm UMRS1131, Institut de Recherche Saint‐Louis, Institut de Génétique Moléculaire, Université de Paris‐Cité, Hôpital St. Louis Paris France
- Department of Medical Biosciences Building 6M, Umeå University Umeå Sweden
- RECAMO, Masaryk Memorial Cancer Institute Brno Czech Republic
| |
Collapse
|
3
|
Salomao N, Karakostis K, Hupp T, Vollrath F, Vojtesek B, Fahraeus R. What do we need to know and understand about p53 to improve its clinical value? J Pathol 2021; 254:443-453. [DOI: 10.1002/path.5677] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 03/25/2021] [Accepted: 04/01/2021] [Indexed: 12/19/2022]
Affiliation(s)
- Norman Salomao
- Inserm UMRS1131, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St Louis Paris France
| | - Konstantinos Karakostis
- Inserm UMRS1131, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St Louis Paris France
| | - Ted Hupp
- University of Gdansk, International Centre for Cancer Vaccine Science Gdansk Poland
- University of Edinburgh, Institute of Genetics and Molecular Medicine Edinburgh UK
| | - Friz Vollrath
- Department of Zoology, Zoology Research and Administration Building University of Oxford Oxford UK
| | | | - Robin Fahraeus
- Inserm UMRS1131, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St Louis Paris France
- University of Gdansk, International Centre for Cancer Vaccine Science Gdansk Poland
- RECAMO, Masaryk Memorial Cancer Institute Brno Czech Republic
- Department of Medical Biosciences Building 6M, Umeå University Umeå Sweden
| |
Collapse
|
4
|
Gnanasundram SV, Malbert-Colas L, Chen S, Fusée L, Daskalogianni C, Muller P, Salomao N, Fåhraeus R. MDM2's dual mRNA binding domains co-ordinate its oncogenic and tumour suppressor activities. Nucleic Acids Res 2020; 48:6775-6787. [PMID: 32453417 PMCID: PMC7337897 DOI: 10.1093/nar/gkaa431] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Revised: 05/05/2020] [Accepted: 05/11/2020] [Indexed: 12/16/2022] Open
Abstract
Cell growth requires a high level of protein synthesis and oncogenic pathways stimulate cell proliferation and ribosome biogenesis. Less is known about how cells respond to dysfunctional mRNA translation and how this feeds back into growth regulatory pathways. The Epstein-Barr virus (EBV)-encoded EBNA1 causes mRNA translation stress in cis that activates PI3Kδ. This leads to the stabilization of MDM2, induces MDM2's binding to the E2F1 mRNA and promotes E2F1 translation. The MDM2 serine 166 regulates the interaction with the E2F1 mRNA and deletion of MDM2 C-terminal RING domain results in a constitutive E2F1 mRNA binding. Phosphorylation on serine 395 following DNA damage instead regulates p53 mRNA binding to its RING domain and prevents the E2F1 mRNA interaction. The p14Arf tumour suppressor binds MDM2 and in addition to preventing degradation of the p53 protein it also prevents the E2F1 mRNA interaction. The data illustrate how two MDM2 domains selectively bind specific mRNAs in response to cellular conditions to promote, or suppress, cell growth and how p14Arf coordinates MDM2's activity towards p53 and E2F1. The data also show how EBV via EBNA1-induced mRNA translation stress targets the E2F1 and the MDM2 - p53 pathway.
Collapse
Affiliation(s)
| | - Laurence Malbert-Colas
- Inserm UMRS1131, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St. Louis, F-75010 Paris, France
| | - Sa Chen
- Department of Medical Biosciences, Building 6M, Umeå University, 901 85 Umeå, Sweden
| | - Leila Fusée
- Inserm UMRS1131, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St. Louis, F-75010 Paris, France
| | - Chrysoula Daskalogianni
- Inserm UMRS1131, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St. Louis, F-75010 Paris, France
| | - Petr Muller
- RECAMO, Masaryk Memorial Cancer Institute, Zlutykopec 7, 65653 Brno, Czech Republic
| | - Norman Salomao
- Inserm UMRS1131, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St. Louis, F-75010 Paris, France
| | | |
Collapse
|
5
|
Maslah N, Salomao N, Drevon L, Verger E, Partouche N, Ly P, Aubin P, Naoui N, Schlageter MH, Bally C, Miekoutima E, Rahmé R, Lehmann-Che J, Ades L, Fenaux P, Cassinat B, Giraudier S. Synergistic effects of PRIMA-1 Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia. Haematologica 2019; 105:1539-1551. [PMID: 31488557 PMCID: PMC7271596 DOI: 10.3324/haematol.2019.218453] [Citation(s) in RCA: 88] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Accepted: 09/04/2019] [Indexed: 12/16/2022] Open
Abstract
Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival with the currently available therapies including chemotherapy and 5-azacitidine (AZA). PRIMA-1Met(APR-246,APR) is a methylated derivative of PRIMA-1, which induces apoptosis in human tumor cells through restoration of the transcriptional transactivation function of mutant p53. Here we show that low doses of APR on its own or in combination with AZA reactivate the p53 pathway and induce an apoptosis program. Functionally, we demonstrate that APR exerts these activities on its own and that it synergizes with AZA in TP53-mutated myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) cell lines and in TP53-mutated primary cells from MDS/AML patients. Low doses of APR on its own or in combination with AZA also show significant efficacy in vivo Lastly, using transcriptomic analysis, we found that the APR + AZA synergy was mediated by downregulation of the FLT3 pathway in drug-treated cells. Activation of the FLT3 pathway by FLT3 ligand reversed the inhibition of cell proliferation by APR + AZA. These data suggest that TP53-mutated MDS/AML may be better targeted by the addition of APR-246 to conventional treatments.
Collapse
Affiliation(s)
- Nabih Maslah
- APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, Paris.,Faculté de Médecine Université Paris Diderot Paris 7, Paris.,INSERM UMR-S 1131, Hôpital Saint-Louis, Paris
| | | | | | - Emmanuelle Verger
- APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, Paris.,INSERM UMR-S 1131, Hôpital Saint-Louis, Paris
| | - Nicolas Partouche
- Faculté de Médecine Paris 12-UPEC, Hôpital Henri Mondor, APHP, Créteil
| | - Pierre Ly
- APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, Paris
| | - Philippe Aubin
- APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, Paris
| | - Nadia Naoui
- APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, Paris
| | - Marie-Helene Schlageter
- APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, Paris.,INSERM UMR-S 1131, Hôpital Saint-Louis, Paris
| | - Cecile Bally
- APHP, Service d'Hématologie Senior, Hôpital Saint-Louis, Paris
| | - Elsa Miekoutima
- APHP, Service d'Hématologie Senior, Hôpital Saint-Louis, Paris
| | - Ramy Rahmé
- APHP, Service d'Hématologie Senior, Hôpital Saint-Louis, Paris
| | - Jacqueline Lehmann-Che
- Faculté de Médecine Université Paris Diderot Paris 7, Paris.,Unité d'Oncologie Moléculaire, Hôpital Saint-Louis, APHP, Paris, France
| | - Lionel Ades
- Faculté de Médecine Université Paris Diderot Paris 7, Paris.,INSERM UMR-S 1131, Hôpital Saint-Louis, Paris.,APHP, Service d'Hématologie Senior, Hôpital Saint-Louis, Paris
| | - Pierre Fenaux
- Faculté de Médecine Université Paris Diderot Paris 7, Paris.,INSERM UMR-S 1131, Hôpital Saint-Louis, Paris.,APHP, Service d'Hématologie Senior, Hôpital Saint-Louis, Paris
| | - Bruno Cassinat
- APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, Paris.,INSERM UMR-S 1131, Hôpital Saint-Louis, Paris
| | - Stephane Giraudier
- Faculté de Médecine Université Paris Diderot Paris 7, Paris .,INSERM UMR-S 1131, Hôpital Saint-Louis, Paris
| |
Collapse
|